196 related articles for article (PubMed ID: 20413063)
21. Combining TBP-based rOFFGEL-IEF with FASP and nLC-ESI-LTQ-MS/MS for the analysis of cisplatin-binding proteins in rat kidney.
Moraleja I; Moreno-Gordaliza E; Mena ML; Gómez-Gómez MM
Talanta; 2014 Mar; 120():433-42. PubMed ID: 24468393
[TBL] [Abstract][Full Text] [Related]
22. Modulation of drug activation profiles through carboxylate ligand modification in cytotoxic trans-platinum planar amine compounds.
Benedetti BT; Quintal S; Farrell NP
Dalton Trans; 2011 Nov; 40(41):10983-8. PubMed ID: 21918760
[TBL] [Abstract][Full Text] [Related]
23. Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action.
Casini A; Hartinger C; Gabbiani C; Mini E; Dyson PJ; Keppler BK; Messori L
J Inorg Biochem; 2008 Mar; 102(3):564-75. PubMed ID: 18177942
[TBL] [Abstract][Full Text] [Related]
24. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients.
Allain P; Heudi O; Cailleux A; Le Bouil A; Larra F; Boisdron-Celle M; Gamelin E
Drug Metab Dispos; 2000 Nov; 28(11):1379-84. PubMed ID: 11038167
[TBL] [Abstract][Full Text] [Related]
25. New platinum(II) complexes containing both an O,O'-chelated acetylacetonate ligand and a sulfur ligand in the platinum coordination sphere induce apoptosis in HeLa cervical carcinoma cells.
Muscella A; Calabriso N; De Pascali SA; Urso L; Ciccarese A; Fanizzi FP; Migoni D; Marsigliante S
Biochem Pharmacol; 2007 Jun; 74(1):28-40. PubMed ID: 17481588
[TBL] [Abstract][Full Text] [Related]
26. Fast cleavage of a diselenide induced by a platinum(II)-methionine complex and its biological implications.
Liu Q; Wang X; Yang X; Liang X; Guo Z
J Inorg Biochem; 2010 Nov; 104(11):1178-84. PubMed ID: 20705343
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
28. Non platinum metal complexes as anti-cancer drugs.
Ott I; Gust R
Arch Pharm (Weinheim); 2007 Mar; 340(3):117-26. PubMed ID: 17315259
[TBL] [Abstract][Full Text] [Related]
29. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
[TBL] [Abstract][Full Text] [Related]
30. Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro.
Sooriyaarachchi M; Narendran A; Gailer J
Metallomics; 2011 Jan; 3(1):49-55. PubMed ID: 21135941
[TBL] [Abstract][Full Text] [Related]
31. Studying the interactions of a platinum(II) 9-aminoacridine complex with proteins and oligonucleotides by ESI-TOF MS.
Samper KG; Vicente C; Rodríguez V; Atrian S; Cutillas N; Capdevila M; Ruiz J; Palacios Ò
Dalton Trans; 2012 Jan; 41(1):300-6. PubMed ID: 22089173
[TBL] [Abstract][Full Text] [Related]
32. The role of bridging ligands in determining DNA-binding ability and cross-linking patterns of dinuclear platinum(II) antitumour complexes.
Zhu J; Lin M; Fan D; Wu Z; Chen Y; Zhang J; Lu Y; Guo Z
Dalton Trans; 2009 Dec; (48):10889-95. PubMed ID: 20023919
[TBL] [Abstract][Full Text] [Related]
33. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
34. New techniques in the pharmacokinetic analysis of cancer drugs. II. The ultratrace determination of platinum in biological samples by inductively coupled plasma-mass spectrometry.
McKay K
Cancer Surv; 1993; 17():407-14. PubMed ID: 8137350
[TBL] [Abstract][Full Text] [Related]
35. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
[TBL] [Abstract][Full Text] [Related]
36. Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line.
Mauldin SK; Husain I; Sancar A; Chaney SG
Cancer Res; 1986 Jun; 46(6):2876-82. PubMed ID: 3698013
[TBL] [Abstract][Full Text] [Related]
37. NMR studies of models having the Pt(d(GpG)) 17-membered macrocyclic ring formed in DNA by platinum anticancer drugs: Pt complexes with bulky chiral diamine ligands.
Saad JS; Benedetti M; Natile G; Marzilli LG
Inorg Chem; 2011 May; 50(10):4559-71. PubMed ID: 21510625
[TBL] [Abstract][Full Text] [Related]
38. The developmental neurotoxicity study of platinum compounds. Effects of cisplatin versus a novel Pt(II) complex on rat cerebellum.
Cerri S; Piccolini VM; Santin G; Bottone MG; De Pascali SA; Migoni D; Iadarola P; Fanizzi FP; Bernocchi G
Neurotoxicol Teratol; 2011; 33(2):273-81. PubMed ID: 20883777
[TBL] [Abstract][Full Text] [Related]
39. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
40. Platinum(II) compounds with chelating ligands based on pyridine and pyrimidine: synthesis, characterizations, DFT calculations, cytotoxic assays and binding to a DNA model base.
Roy S; Westmaas JA; Buda F; Reedijk J
J Inorg Biochem; 2009 Sep; 103(9):1278-87. PubMed ID: 19656572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
